Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Panacea Life Sciences Holdings Cash-to-Debt?
Panacea Life Sciences HoldingsPLSH +11.93% Cash-to-Debt is 0.03 as of Sep. 2025, which is 25% below its 10-year median of 0.04. The stock has 10 warning signs investors should review. Among 950 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks worse than 94.63% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Panacea Life Sciences Holdings's cash to debt ratio for the quarter that ended in Sep. 2025 was 0.03.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Panacea Life Sciences Holdingscouldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2025.
The historical rank and industry rank for Panacea Life Sciences Holdings's Cash-to-Debt or its related term are showing as below:
PLSH'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.65
Current: 0.03
During the past 4 years, Panacea Life Sciences Holdings's highest Cash to Debt Ratio was 0.65. The lowest was 0.00. And the median was 0.04.
PLSH's Cash-to-Debt is ranked worse than 94.63% of 950
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs PLSH: 0.03
Panacea Life Sciences Holdings (OTCPK:PLSH) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Panacea Life Sciences Holdings Cash-to-Debt Related Terms
Panacea Life Sciences Holdings Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Life Sciences Holdings Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings (PLSH) has a Cash-to-Debt of 0.03 as of Sep. 2025. This is 25% below median its historical median of 0.04. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #899 out of 950 companies in the Drug Manufacturers industry, placing it in the top 94.6%.
Is Panacea Life Sciences Holdings' Cash-to-Debt too high?
Panacea Life Sciences Holdings' current Cash-to-Debt of 0.03 is 25% below median its 10-year median of 0.04. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Panacea Life Sciences Holdings' value of 0.03 is 96.9% below this industry median. Based on the distribution chart, Panacea Life Sciences Holdings ranks #899 out of 950 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Panacea Life Sciences Holdings' Cash-to-Debt compare to SHPH and SKYI?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #899 out of 950 companies for Cash-to-Debt. This places Panacea Life Sciences Holdings in the lower half of its industry. The industry median Cash-to-Debt is 0.98. Panacea Life Sciences Holdings' value of 0.03 is 96.9% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.98, Panacea Life Sciences Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Life Sciences Holdings's current Cash-to-Debt of 0.03 is 96.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current Cash-to-Debt is 0.03, which is 25% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current Cash-to-Debt of 0.03. The current Cash-to-Debt is 0.03, which is 25% below median its 10-year median of 0.04 and 96.9% below the Drug Manufacturers industry median of 0.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current Cash-to-Debt is 0.03 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSH has been successfully added to your 
